Innovative Gene Therapy for
Alzheimer's Disease
Introduction
Alzheimer's disease is a multifactorial condition, and the development of a successful therapy requires not only considering the full spectrum of biological disturbances (factors) associated with the disease but also ranking them by significance with a mandatory assessment of the scientific and experimental evidence pertaining to each.
Our pioneering genetic pharmaceutical represents a breakthrough in Alzheimer's Disease (AD) treatment - CG-AD211 - integrating proven methods with cutting-edge biotechnology. We focus on two major therapeutic objectives:
-
Clearance of Intracellular Pathological Protein Aggregates
-
Neuroregeneration in Affected Brain Regions
facts
55 000 000
people worldwide are living with dementia, and up to 70% of them have Alzheimer’s disease
Source: World Health Organization, 2023
$2 trillion
estimated global economic cost of dementia by 2030 if current trends continue
Source: Alzheimer’s Disease International, World Alzheimer Report 2023
80%
of Alzheimer’s patients require continuous care within 5 years of diagnosis
Source: Alzheimer's Disease International. World Alzheimer Report 2013
Therapeutic Strategy
Our approach targets the core pathological processes of Alzheimer's:​
​
Selective Removal of Intracellular Tau Aggregates: Our innovative therapy directly targets the accumulation of intracellular tau aggregates—recognized as a primary cause of neurodegeneration and cognitive decline in Alzheimer's Disease. Unlike conventional treatments primarily aimed at reducing inflammation or managing secondary symptoms, our approach tackles the underlying pathology by facilitating the intracellular disposal of tau proteins. Currently, no other treatment provides this targeted solution.
​
Promoting Neuroregeneration: By leveraging native human genes, our therapy actively stimulates multiple regeneration processes within the brain. It supports damaged neurons in their recovery and enhances their capability to re-establish functional synaptic connections. Additionally, our therapy provides robust neuroprotective effects, safeguarding existing neurons from further degeneration. This combined approach of neuron repair and neuroprotection ensures effective reintegration into existing neural networks, ultimately resulting in significant improvements in cognitive and neurological functions for Alzheimer's patients.
Economic and Clinical Viability
1
Regulatory Compliance
Meets all EMA and FDA standards for safety and efficacy.
The technology meets the most rigorous international EMA and FDA requirements for safety, ensuring a solid regulatory foundation for clinical and commercial applications worldwide.
2
Scalable Production
Compatible with standard biotechnological facilities, ensuring affordability and high profitability.
The platform can be implemented in standard biotech facilities without costly modifications, thereby guaranteeing both affordability for manufacturers and exceptionally high profitability for investors and partners.
3
Market Potential
Addresses an unmet need in an expanding global market, projected to triple by 2050.
The product targets rapidly growing therapeutic markets whose cumulative global value is projected to triple by 2050, offering a long-term opportunity for sustainable expansion.
‘ALZHEIMER’S DISEASE IS THE BIGGEST HEALTH AND SOCIAL CARE CHALLENGE OF OUR GENERATION.’
Alzheimer’s Disease International
Future Expansion
Potential application of our genetic pharmaceutical extends beyond Alzheimer's to other neurodegenerative conditions like Parkinson's Disease, tauopathies, and Multiple Sclerosis, highlighting the versatility and broad therapeutic impact of our innovation.